InMed Pharmaceuticals (INM) Free Cash Flow (2019 - 2026)

InMed Pharmaceuticals has reported Free Cash Flow for 8 years, with the latest figure at -$1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 2.15% year-over-year to -$1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$7.5 million (down 6.27% YoY), and the FY2025 full-year result was -$7.8 million, down 11.03% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$1.7 million, up from -$2.4 million in the prior quarter.
• The five-year high for Free Cash Flow was -$689750.0 in Q2 2023, with the low at -$5.4 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$2.2 million across 5 years, with a median of -$1.8 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 101.75% — and 2023, when it surged 82.96%.
• InMed Pharmaceuticals' Free Cash Flow stood at -$2.7 million in 2022, then jumped by 31.88% to -$1.8 million in 2023, then plunged by 35.39% to -$2.5 million in 2024, then climbed by 5.03% to -$2.4 million in 2025, then grew by 28.66% to -$1.7 million in 2026.
• The last three Free Cash Flow figures came in at -$1.7 million (Q1 2026), -$2.4 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.